JUN 21, 2016 9:22 AM PDT

New vaccine offers better way to prevent pneumonia

Current vaccines target only a small percentage of the more than 90 strains of the bacteria that cause pneumonia. But researchers say a new protein-based vaccine can defend against many more strains—and that it’s 100 percent effective at promoting the appropriate immune response.
 

Image Credit: iStockphoto

Computer simulations indicate the vaccine would be effective against all strains of pneumococcus, but additional tests are needed to confirm that.

The vaccine offers what could be the most direct and broad response to preventing pneumonia—the leading cause of death of children under the age of 5 worldwide, according to the World Health Organization—as well as meningitis, sepsis, and other serious infections caused by pneumococcus.

“These are very serious illnesses that we haven’t been able to completely suppress. The vaccine we’re developing could finally get that job done,” says Blaine A. Pfeifer, an associate professor of chemical and biological engineering at the University at Buffalo School of Engineering and Applied Sciences.

Pfeifer led the study, published in the Proceedings of the National Academy of Sciences, with former student Charles H. Jones, who is overseeing efforts to commercialize the vaccine.

“With conventional vaccines, the approach has been: ‘What bacteria do we want to target and how,'” says Jones, CEO and founder of Abcombi Biosciences. “Our strategy is to shift the paradigm to which diseases do we want to prevent.”

To treat and prevent illnesses caused by pneumococcus, doctors almost exclusively relied on penicillin and other common antibiotics. While still used, the effectiveness of these drugs has been waning for decades due to bacteria developing antibiotic resistance.

The situation led pharmaceutical companies to develop preventative vaccines, which have reduced deaths and illnesses, especially in developed nations. But pneumococcus remains a serious problem.

Pneumonia killed 1.3 million people worldwide in 2011, with the majority of deaths in Sub-Saharan Africa and South Asia. In the United States alone, pneumonia, meningitis, and sepsis cause tens of thousands of deaths each year, according to the National Foundation for Infectious Diseases.

One reason for this is that current vaccines, which identify pneumococcus by a sugar coating that surround the bacteria, are 56 to 88 percent effective.
 

Why this vaccine is different


The new vaccine identifies strains by proteins attached to the surface of pneumococcus. Laboratory tests show the vaccine can defend against more than 12 strains.

“It’s like the arcade game Whac-A-Mole. Think of the mallet as a traditional vaccine. It can’t stop all the moles, or in our case, all the strains of bacteria at once,” Jones says. “But our vaccine does just that. It’s like a mallet with 90 heads that strikes all the moles simultaneously.”

The new vaccine also differs from what’s on the market by its response to the bacteria.

Current vaccines teach the immune system to indiscriminately destroy bacteria and other pathogens. The approach works, but there is growing concern that it can create space within the body for new and potentially more harmful alternatives to establish residence—similar to antibiotic resistance resulting in new and more potent pathogens.

The new vaccine allows bacteria to exist as long as it causes no harm to body. It instructs the immune system to attack only when the surface proteins, mentioned above, break free of the bacterial coating.

“That’s the signal that this bacteria is becoming a troublemaker, that’s its threatening the body, and that it’s necessary to fight back,” Pfeifer says.

The National Institutes of Health, Swedish Medical Research Council, and the Arthur A. Schomburg Fellowship Program at the University at Buffalo funded the work.

Source: University at Buffalo

This article was originally published on futurity.org.
About the Author
  • Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
AUG 06, 2019
Microbiology
AUG 06, 2019
Lab Mice Born to Moms From the Wild Make Better Research Models
A standard research mouse genotype was preserved while generating a natural microbiome by using wild mice as surrogates....
SEP 11, 2019
Cardiology
SEP 11, 2019
Better Sleep, Brought To You By Exercise
Regular difficulty falling or staying asleep, called chronic insomnia, is the most common sleep disorder among adults. In the search for better, more restf...
NOV 27, 2019
Drug Discovery & Development
NOV 27, 2019
Vaccine Causes More Polio Cases than Wild Virus
The World Health Organization (WHO) has confirmed that 11 new cases of polio in five African countries including Nigeria, Congo and Angola were caused by a...
DEC 20, 2019
Neuroscience
DEC 20, 2019
Does Having Herpes Increase Your Risk for Alzheimer's?
Around 44 million people around the world have Alzheimer’s disease, a progressive form of dementia that leads to memory loss and a decline in cogniti...
JAN 14, 2020
Technology
JAN 14, 2020
Can Virtual Reality Influence an Increase in Vaccinations?
Can a virtual reality (VR) help increase flu vaccination rates? Apparently, yes! A recent study using VR stimulation is aiming to show how the flu spreads ...
FEB 12, 2020
Drug Discovery & Development
FEB 12, 2020
Does Traditional Chinese Medicine Work Against Coronavirus?
Over 45,000 cases of Wuhan Coronavirus have been reported globally, alongside over 1,100 deaths. Although over 4,700 people are said to have recovered from...
Loading Comments...